Media headlines about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) have been trending somewhat negative recently, Accern reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adamis Pharmaceuticals Corporation earned a news impact score of -0.06 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 63 out of 100, indicating that recent press coverage is somewhat likely to have an impact on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Adamis Pharmaceuticals Corp (ADMP) Watching the MFI Levels Intensely – FLBC News (flbcnews.com)
- Adamis Pharmaceuticals Corp (ADMP) Showing Negative Momentum in the Technicals – Evergreen Caller (evergreencaller.com)
- Adamis Pharmaceuticals Corp (ADMP) Trending Downward Near-term – FLBC News (flbcnews.com)
- Analysts said to Buy Healthcare Stock: Adamis Pharmaceuticals Corporation (ADMP) ,Repligen Corporation (RGEN) – Street Observer (press release) (streetobserver.com)
- Adamis Pharmaceuticals Corporation (ADMP) and Juniper Pharmaceuticals (JNP) Critical Review (americanbankingnews.com)
ADMP has been the topic of several recent research reports. Maxim Group restated a “buy” rating and set a $10.00 target price on shares of Adamis Pharmaceuticals Corporation in a report on Monday, June 12th. ValuEngine upgraded Adamis Pharmaceuticals Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 16th.
Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) remained flat at $4.60 on Tuesday. The company had a trading volume of 207,353 shares. The stock’s 50 day moving average price is $5.02 and its 200 day moving average price is $4.16. Adamis Pharmaceuticals Corporation has a 1-year low of $2.40 and a 1-year high of $6.45. The stock’s market cap is $126.79 million.
COPYRIGHT VIOLATION NOTICE: “Somewhat Critical Media Coverage Somewhat Likely to Affect Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Share Price” was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/somewhat-negative-media-coverage-somewhat-likely-to-impact-adamis-pharmaceuticals-corporation-nasdaqadmp-stock-price-updated-updated-updated/1194346.html.
About Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with our FREE daily email newsletter.